Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

INTRODUCTION: Prior research has demonstrated that early treatment with high-efficacy disease-modifying therapies (DMTs), including ocrelizumab (OCR), can reduce relapses and delay disease progression among persons with multiple sclerosis (pwMS) compared with escalation from low-/moderate-efficacy D...

Descripción completa

Detalles Bibliográficos
Autores principales: Geiger, Caroline K., Sheinson, Danny, To, Tu My, Jones, David, Bonine, Nicole G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444704/
https://www.ncbi.nlm.nih.gov/pubmed/37458897
http://dx.doi.org/10.1007/s40120-023-00523-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444704/
https://www.ncbi.nlm.nih.gov/pubmed/37458897
http://dx.doi.org/10.1007/s40120-023-00523-3

Ejemplares similares